Helen Torley
CIK 1528185 · PRESIDENT AND CEO · last filed 2026-07-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$80.06M
Companies
5
Total Filings
141
Lifetime Open-Market Net
-$87.82M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HALO | PRESIDENT AND CEO | 769,703 | $102.08 | $78.57M | -$153.4K | 1 | 2026-07-09 |
| HTI | PRESIDENT AND CEO | 767,780 | — | — | -$83.25M | 89 | 2026-06-03 |
| DGX | Director | 6,260 | $238.03 | $1.49M | $0 | 7 | 2021-05-25 |
| Relypsa Inc (RLYP) Delisted | Director | 0 | — | — | -$19.6K | 5 | 2016-09-02 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | EVP, Chief Commercial Officer | 35,911 | — | — | -$4.40M | 14 | 2013-09-05 |
Recent Filings · Page 14 of 15
141 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-04-03 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Sell (S) | −466 | -$40.1K | EDGAR |
| 2013-04-01 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Grant (A) | +8,600 | $0 | EDGAR |
| 2013-02-06 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Mixed | — | -$365.5K | EDGAR |
| 2012-11-30 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Mixed | −3,747 | -$619.4K | EDGAR |
| 2012-10-05 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Sell (S) | −2,314 | -$200.2K | EDGAR |
| 2012-09-06 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Sell (S) | −1,878 | -$136.7K | EDGAR |
| 2012-08-08 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Sell (S) | −2,000 | -$143.8K | EDGAR |
| 2012-07-27 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Sell (S) | −4,549 | -$336.5K | EDGAR |
| 2012-04-03 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Grant (A) | +20,750 | $0 | EDGAR |
| 2011-10-27 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.